A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjogren's Syndrome
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs AMG 557 (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Sponsors MedImmune
- 22 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Jul 2017 Planned End Date changed from 1 Jan 2018 to 16 Aug 2018.
- 11 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 7 Feb 2018.